ReviewOphthalmology and therapy2026
Postoperative Inflammation and Pain Management with Intracanalicular Dexamethasone Insert: Real-World Applications.
Review in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTransient pain and ocular inflammation may occur with ophthalmic surgery. Pain is an important determinant of patient satisfaction, and inflammation can increase the risk for suboptimal visual outcomes. Topical anti-inflammatory therapies can reduce the incidence of postoperative pain and inflammation but have many limitations, including nonadherence and significant potential side effects such as cataract formation and intraocular pressure elevation. There is unmet need for a therapy that provides anti-inflammatory and analgesic activity while overcoming the limitations of topical therapy. The intracanalicular dexamethasone insert (DEX) overcomes many of the limitations of topical therapy. DEX is a fluorescent yellow cylindrical-shaped polyethylene glycol-based hydrogel insert incorporating 0.4 mg preservative-free dexamethasone. The insert was designed based on human anatomy and measurements of the canalicular system and continuously releases a tapered dose of dexamethasone over approximately 30 days onto the surface of the eye. The insert is completely resorbable and does not require removal. DEX was approved by the US Food and Drug Administration for the treatment of pain (in 2018) and inflammation (in 2019) following ocular surgery; in 2021, the treatment of ocular itching associated with allergic conjunctivitis was added as an indication. AREAS COVERED: We present a comprehensive review of the current therapeutic landscape for management of postoperative pain and inflammation following cataract surgery, including the limitations of topical eye drop medications. We review data from the key phase 2 and 3 clinical trials that supported the approval and label expansion for DEX. We also summarize the broader literature of smaller studies evaluating the role of DEX in controlling postoperative pain and inflammation for a variety of ophthalmic surgery beyond cataract surgery as well as in management of ocular itching associated with allergic conjunctivitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.